These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31394922)

  • 1. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer.
    Luhn P; Chui SY; Hsieh AF; Yi J; Mecke A; Bajaj PS; Hasnain W; Falgas A; Ton TG; Kurian AW
    J Comp Eff Res; 2019 Oct; 8(14):1173-1185. PubMed ID: 31394922
    [No Abstract]   [Full Text] [Related]  

  • 2. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
    N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice.
    O'Shaughnessy J; Emens LA; Chui SY; Wang W; Russell K; Lin SW; Flores Avile C; Luhn P; Schneeweiss A
    Curr Oncol; 2021 Jul; 28(4):2741-2752. PubMed ID: 34287291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer.
    Li Y; Zhao Y; Gong C; Xie Y; Hu X; Zhang J; Wang L; Zhang S; Cao J; Tao Z; Wang B
    Sci Rep; 2019 Mar; 9(1):3563. PubMed ID: 30837503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Li CH; Karantza V; Aktan G; Lala M
    Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer.
    Li J; Zhang T; Lu P; Zhao J; Chen L; Jiang J
    Immunotherapy; 2020 Jul; 12(10):705-713. PubMed ID: 32522057
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
    Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
    Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
    Hamilton E; Kimmick G; Hopkins J; Marcom PK; Rocha G; Welch R; Broadwater G; Blackwell K
    Clin Breast Cancer; 2013 Dec; 13(6):416-20. PubMed ID: 24099649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
    Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
    Adams S; Diéras V; Barrios CH; Winer EP; Schneeweiss A; Iwata H; Loi S; Patel S; Henschel V; Chui SY; Rugo HS; Emens LA; Schmid P
    Ann Oncol; 2020 May; 31(5):582-589. PubMed ID: 32178964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
    Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
    Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
    Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Jan; 38(1):379-383. PubMed ID: 29277798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
    Kang C; Syed YY
    Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.
    Cortes J; Pérez-García J; Whiting S; Wan Y; Solem C; Tai MH; Margunato-Debay S; Ko A; Fandi A; Botteman M
    Clin Breast Cancer; 2018 Oct; 18(5):e919-e926. PubMed ID: 29703690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.
    Forero-Torres A; Varley KE; Abramson VG; Li Y; Vaklavas C; Lin NU; Liu MC; Rugo HS; Nanda R; Storniolo AM; Traina TA; Patil S; Van Poznak CH; Nangia JR; Irvin WJ; Krontiras H; De Los Santos JF; Haluska P; Grizzle W; Myers RM; Wolff AC;
    Clin Cancer Res; 2015 Jun; 21(12):2722-9. PubMed ID: 25779953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of taxanes in triple-negative breast cancer: literature review.
    Mustacchi G; De Laurentiis M
    Drug Des Devel Ther; 2015; 9():4303-18. PubMed ID: 26273192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
    Wang H; Ma H; Sové RJ; Emens LA; Popel AS
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.
    Liang C; Li L; Fraser CD; Ko A; Corzo D; Enger C; Patt D
    BMC Cancer; 2015 Dec; 15():1019. PubMed ID: 26714468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
    Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.